Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients | Zendy

Esben Thyssen Vestergaard | Zendy; Astrid Hjelholt | Zendy; Rune E. Kuhre | Zendy; Niels Møller | Zendy; Pierre Larraufie | Zendy; Fiona M. Gribble | Zendy; Frank Reimann | Zendy; Niels Jessen | Zendy; Jens J. Holst | Zendy; Jens Otto Lunde Jørgensen | Zendy

AI Assistant Blog Pricing

Open Access

Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients

Author(s) -

Esben Thyssen Vestergaard,

Astrid Hjelholt,

Rune E. Kuhre,

Niels Møller,

Pierre Larraufie,

Fiona M. Gribble,

Frank Reimann,

Niels Jessen,

Jens J. Holst,

Jens Otto Lunde Jørgensen

Publication year - 2019

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2018-02503

Subject(s) - medicine , endocrinology , lipolysis , type 2 diabetes , insulin , adipose tissue , basal (medicine) , incretin , diabetes mellitus

Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in type 2 diabetes and obesity. The interplay between ambient free fatty acids (FFAs) and GLP-1 remains unclear. Acipimox suppresses adipose tissue lipolysis via activation of the PUMA-G (also known as HCA2 and GPR109a) receptor.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog